Analysis of sponsor hearings on health technology assessment decision making.

ConclusionThe PBAC considered approximately 45% of sponsor hearings to be informative or moderately informative whereas 18% were classed as uninformative.What is known about the topic?Although the sponsors of medicines being considered by the Pharmaceutical Benefits Advisory Committee (PBAC) for public subsidy have been able to give a 10 min presentation to the Committee at the time of decision making for several years, it is unknown whether these hearings are beneficial.What does this paper add?We present what is believed to be the results of the first analysis of PBAC sponsor hearings.What are the implications for practitioners?All stakeholders should consider the findings of our research and associated recommendations to ensure that future sponsor hearings enhance PBAC decision making and promote good public health policy. PMID: 31072455 [PubMed - as supplied by publisher]
Source: Australian Health Review - Category: Hospital Management Authors: Tags: Aust Health Rev Source Type: research